Pfizer Cash Helps Boost Xoma’s 2007 Revenue
This article was originally published in The Pink Sheet Daily
Position is strong as type 2 diabetes candidate advances.
You may also be interested in...
$250,000 per year wholesale acquisition cost to treat rare genetic disorder, firm tells “The Pink Sheet” DAILY.
Antibody developer’s near-term focus is on advancing its anti-inflammatory agent 052 and antimicrobial peptide 629 and partnering Neuprex.
Xoma 052 targets interleukin-1 beta to stop destruction of pancreatic cells.